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To determine causes of delayed puberty in a referral population, we analyzed 137 children seen between 1975-84. Pubertal delay was defined in males as testicular volume <2cc beyond age 14 and in females as lack of breast development by age 13 or failure of menarche by age 15 years. Common complaints at clinical presentation included short stature or decreased growth in 82%, delayed puberty in 35%, amenorrhea in 28% of females, signs of intracranial tumor in 3.6%, and evidence of chronic disease in 12%. We obtained height, weight, growth rate, body proportions, parental heights, family history of delay, and Tanner staging. When indicated we measured thyroid function, bone age, gonadotropin and sex hormone levels, growth hormone responses and performed chromosome analysis, skull X-ray or CT scan. 65 patients had a final diagnosis of constitutional pubertal delay; 40% of these had a family history of delay. 46 children had delayed puberty secondary to hypothalamic-pituitary dysfunction. Of 24 who were idiopathic, 7 had isolated gonadotropin deficiency and 17 had other pituitary abnormalities. Six others had congenital anomalies such as septo-optic dysplasia or Kallman's syndrome. The remaining 16 patients had tumors in the pituitary region, of which 7 were craniopharyngiomas. Eleven children had primary gonadal failure with 6 having Turner's syndrome. Two girls with amenorrhea presented with genital tract anatomic anomalies. The last 13 patients had delayed puberty secondary to associated medical problems or chronic disease. Delayed puberty appears most often to be due to constitutional delay, associated with a positive family history, and to idiopathic involvement of the hypothalamic-pituitary axis. (Table) . In the boys '~ith HH, the maximal serum levels of prolactin vere completely separate from the levels of the controls. Nevertheless, the maximal levels of prolactin were subnormal (=below the 90% confidence ranges of the controls) in 819 boys with HH. All the boys with D had normal maximal levels of prolactin. The maximal levcls of LH were subnormal Tn only 319 boys and those of FSH in ~J / S :r~:?s with EH. Metoclopramide test appears to be effective in rcrther improving the differentiation of HH and D.
A search Cor the lowest dose of oxandrolone which is effective for the treatnent of constitutional delay 185 of growth and puberty in boys.
The !liddlesex Hospital, London W1, UK 24 boys, mean age 14.6 yrs, with a delayed pubertal growth spurt were treated with oxandrolone 2.5 mg daily for a mean of 0.3 yr (range 0.21 to 0.65 y r ) . Mean increment of growth velocity, compared with pretreatment values, was 4.4 cmlyr during the treatnent period and 3.7 cnlyr following cessation of treatment. This effect was not due to a spantaneous growth acceleration as mean testicular volume at the start of treatment was 8.4 ml and 9.3 ml at the end of treatment. There was no significant change in height for bone age SDS and no side effects. All patients had normal pubertal progression during and after treatment.
Following this experience we have used an even lower dose of oxandrolone, 1.25 ag daily, for n mean period of 0.26 y r (range 0.22 -0.38 yr) with an additional 15 boys, mean age 14.7 yr, with slnlilar results. Although we have still not yet defined the minimum dose, 1.25 mg daily for 3 months is safe, effective and much less than has previously been recommended.
Ke have investigated the mode of action of oxandrolone using 24 hour serum profiles of CH, gonadotrophins and testosterone. during A (p < 0.05) . The mean testosterone value (pg/c?l) was 257i20 before and 23+5 during A (p<0.001). It is concluded that the A used In this study is effectivein inhibltmgpuberty in boys and girls. It was very well accepted and there were no evident side effects except for temporary local pain. The lenght of treatment in our subjects does not allow a prediction of the effect on final height, but the clinical and hormonal data in hands are favorable.
INTRANASAL TREATMENT OF PRECOCIOUS PUBERTY (PP)
1 87 IUTH A LONG-ACTTNG I H-RH-ANALOGUE.
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5 g i r l s w i t h t r u e PP (4-8 y e a r s ) , demonstrating c l i n i c a l s i g n s of puberty, a c c e l e r a t e d growth v e l o c i t y , advanced bone age and p u b e r t a l LH/FSH l e v e l s o f g o n a d o t r o~h i n s , were t r e a t e d w i t h an i n t r a n a s a l spray o f t h e LH-RH-analogue 0-Ser (TBU)~-LH-RH-EA ( B u s e r e l i n ( 6 ) ) f o r 6 t o 9 months. Therapy was s t a r t e d w i t h 8x300 pg Blday i n t r a n a s a l l y (150 ug p e r p u f f i n t o each n o s t r i l ) f o r 2 weeks, followed by a maintenance dose o f 3x300 pg/day.When spontaneous LH/FSH-secretion d u r i n g t h e n i g h t ( 2 0 min.samp1 i n g i n t e r v a l s from o t o 4 a.m.) b e f o r e and 7 days a f t e r b e g i n n i n g o f t h e t r e a t m e n t was compared, 2 g i r l s showed a s l i g h t r i s e o f median LH values (3.5 t o 6.5 mIU/ml) and t o o t h e r s a decrease (18 t o 9 mIU/ml). Only one had 2 spontaneous b u r s t s o f s e c r e t i o n t h a t d i d n o t occur o i~-t h e r a~y one week l a t e r . Whereas measurements o f LH/FSH, E2 and t e s t o s t e r o n e a f t e r 1, 3, 6 and 9 months of B-treatment suggested continued suppression o f t h e p i t u i t a r y - Opioid peptides exert a tonic inhibitory effect an LH secretion, acting at the hypothalamic level in modulating LHRH release. Naloxone, an opiate receptor antagonist, has been used to evaluate the activity of such tonus. Previous data have demonstrated Naloxone inefficacy on circulating LH in prepuberal children. The present study refers the effects of Naloxone (0.08 mg/kg.B;v., i.v.) and LH-RH (50 mcg i.v.) in healthy subjects subdivided according to puberal development, in 5 precocious and in 7 delayed puberty. In the normal controls and in precocio -us puberty patients,uhile LH-RH induced a significant rise of LH levels correlated to the puberal stages, Naloxone induced a n LH increase only after P stage (P<0.01). In the group of delayed puberty LH-RH stimulation increased : H levels in all subjects and,on the contrary,Naloxone was unable to modify circulating LH levels in all subjects. These data may suggest that the Function of opiotergic neurons involved in the inhibitory control of LH secretion become active at the more advanced stages of ouberty, indipendently From the age of the subjects or from the age of the onset of puberty. T h i s assumption corroborate the concept that gonadal steroids play a fundamental role in modulating the tonus of central opioid system and support the hypothesis that the opiaid system is involved in the neuroendocrine events of puberal maturation.
